Year: 2025
Type: article
Study design: Case Report
Abstract: Introduction: Intratumoral delivery of conventional dendritic cells (cDC1) offers a promising new immunotherapy strategy for HER2-positive breast cancer by activating CD4⁺ Th1 cells and other innate immune components.Case presentation: We present a case series of two young women presenting with de novo metastatic HER2-positive breast cancer treated with cDC1 therapy alongside HER2-targeted and endocrine therapies.The patients tolerated the treatment well and showed encouraging outcomes, including tumor reduction, healing of metastatic sites and early immune responses before starting chemotherapy.Imaging revealed significant partial responses or no active disease, and blood analyses confirmed immune activation.Conclusion: These findings demonstrate the feasibility and safety of cDC1 intratumoral therapy as an early intervention and suggest its potential role in improving clinical outcomes.Further research is warranted to refine patient selection and treatment regimens for optimal integration into standard care for metastatic HER2-positive breast cancer.
Source: Annals of Case Reports
Authors: Eliana Burgos, Paige Aiello, Amy Aldrich, Robert Weinfurtner, Brian J Czerniecki, Aixa E Soyano
Institutions: University of South Florida, Moffitt Cancer Center
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: diamond
Funder: Moffitt Cancer Center
OpenAlex ID: W4413416166